Core Insights - BrightSpring Health Services, Inc. (BTSG) is positioned to capitalize on the trend of complex care moving from hospitals to home settings, which increases demand for medication access and coordinated clinical services [1] - The company anticipates sequential improvement in 2026, with profitability expected to grow faster than revenue due to efficiency initiatives [1] Company Overview - BrightSpring operates a national home- and community-based platform that integrates pharmacy capabilities with provider care for medically complex patients across various payors [2] - The company is headquartered in Louisville, KY, and serves all 50 states [2] Operational Segments - Operations are divided into two segments: Pharmacy Solutions, focusing on medication dispensing and therapy management, and Provider Services, delivering clinical care primarily in the home [3] - Pharmacy Solutions generated $11.4 billion, or 88.7% of total revenue in fiscal 2025, while Provider Services contributed $1.5 billion, or 11.3% [5] Revenue Growth - In fiscal 2025, revenue reached $12.9 billion, a 28.2% increase from $10.1 billion in 2024 [5] - Specialty and infusion within Pharmacy Solutions grew to $9.1 billion, reflecting a significant growth trajectory [6] Payor Mix - The 2025 payor mix included Medicare Part D at 31.7%, Medicare Advantage at 17.6%, commercial at 24.1%, and Medicaid at 8.5% [7] Growth Catalysts - Specialty and infusion are identified as primary growth drivers, with a 43% year-over-year growth in Q4 [8][10] - Management expects over 16–20 limited-distribution launches in the next 12–18 months, which will enhance script volume and clinical management work [9] Financial Projections - For 2026, BTSG projects revenue between $14.45 billion and $15.0 billion, with adjusted EBITDA expected to be between $760 million and $790 million [12] - Provider Services is anticipated to grow at mid-to-high 20% rates, supported by the acquisition of Amedisys/LHC assets [13] Margin Expansion - Margin expansion in 2026 is expected to be driven by a shift towards higher-value specialty and infusion work, efficiency programs, and pricing initiatives [11] - A midyear generic launch in Q2 2026 is also expected to contribute positively to margins [12] Challenges and Mitigation - Home and community pharmacy faces near-term headwinds affecting script growth, attributed to offboarded customers and bankruptcies [16] - Management's mitigation plan includes targeted market focus, new sales hires, and pricing initiatives to stabilize growth [17][18] Monitoring Key Developments - Key developments to watch in 2026 include the cadence of limited-distribution drug wins, the timing of the generic launch, and integration milestones related to the Amedisys/LHC assets [19][20] Competitive Landscape - The home-based care landscape remains competitive, with significant players like Option Care Health and CVS Health, making execution and access critical for BTSG [21]